How, if at all, will you incorporate durvalumab + FLOT in patients with HER2+ resectable gastric/GEJ adenocarcinoma?

Currently, there are no approved biomarker-driven targeted therapies for patients with locally advanced resectable gastric/GEJ adenocarcinoma. While data from the metastatic setting have consistently demonstrated improved outcomes with the addition of HER2-targeted therapies to chemotherapy in HER2-...

At this time, the treatment of HER2+ EG adenocarcinoma is exactly the same as that of HER2- disease. Indeed, the only biomarker-selected population for which we would consider anything other than durvalumab/FLOT is the dMMR/MSI population.

There are several studies that have evaluated the addition of...